It has been shown in animal models 6 and in retrospective analyses of clinical studies of BMT for leukemias and lymphomas, that the development of GVHD following allogeneic BMT may be beneficial and correlate with a graftversus-leukemia (GVL) response. 7, 8 Allogeneic BMT recipients who develop acute or chronic GVHD have lower relapse rates than patients transplanted with autologous or syngeneic BM. 9, 10 Furthermore, when patients undergoing allogeneic transplants are given T cell-depleted BM to eliminate GVHD, increased relapse rates occur, suggesting that T cells present in the donor graft are necessary for inhibition of leukemic relapse. 11 Cytotoxic T lymphocytes (CTL), 12 lymphokine-activated killer cells, 13 and natural killer cells (NK) 14 are all thought to participate in the GVL process. Recently, much effort has been expended to discriminate beneficial GVL responses from the harmful GVHD effector mechanisms. In murine models of GVHD, it has been possible to separate GVHD immune mechanisms from GVL responses. 7 However, such findings have not yet been extrapolated to man.
Interestingly, rodents treated with the immunosuppressive drug cyclosporin A (CsA) following syngeneic or autologous BMT develop a disease similar to allogeneic GVHD. [15] [16] [17] Although the mechanism(s) by which CsA treatment of syngeneic reconstituted animals induces syngeneic GVHD (SGVHD) is not totally understood, CsA-induced autologous GVHD has been used in cancer patients post-transplant to assess the antitumor effects. [18] [19] [20] [21] [22] [23] [24] A low-grade cutaneous GVHD which spontaneously regressed was induced in a high percentage of the patients following autologous transplantation and CsA treatment. Isolated T cells from such patients showed the ability to lyse autologous peripheral blood lymphocytes in vitro. 18, 24 However, the ability of the inducible GVHD disease to mediate GVL activity in vivo and reduce relapse rates remains unclear. Recently, Noga et al 25 have shown that rats with CsA-induced SGVHD demonstrated an antitumor effect against a minimal tumor burden of a class II ϩ syngeneic B cell tumor. This antitumor response could be further enhanced by IFN-␥, which upregulated tumor class II molecules in vivo making the tumor cells more susceptible to the proposed effector cells of rat SGVHD, class II-reactive, autoreactive CTL. 26 We have been successful in inducing a GVHD-like syndrome in C3H/HeN mice following cessation of a short course of CsA therapy given to lethally irradiated syngeneic BMT mice 17, 27, 28 and in this manuscript address the ability of murine SGVHD to mediate GVL responses. The data demonstrate that mice which are inducible for SGVHD mediate the rejection of a primary, but not a secondary challenge with a syngeneic class II Ϫ B cell lymphoma suggesting that T cellmediated tumor-specific immunity did not develop in such animals. Consistent with these findings was the presence of enhanced NK activity after induction of SGVHD and the absence of demonstrable antitumor T cell activity.
Materials and methods

Mice and tumor
C3H/HeN mice (National Cancer Institute, Frederick, MD, USA; Harlan Sprague Dawley, Indianapolis, IN, USA) were purchased at 3 weeks of age and were used within 1 week of arrival. Mice were given acidified drinking water and autoclaved lab food ad libitum and were housed in sterile Microisolator boxes (Lab Products, Maywood, NJ, USA). The carcinogen-induced C3H B cell lymphoma, 38C13, has previously been described by Bergman and Haimovitch 29 and was kindly provided by Dr Ronald Levy, Stanford University. The tumor cells were used from a common frozen stock and were grown for 1-2 weeks prior to injection. Intravenous injection of 500-1000 tumor cells into normal C3H/HeN mice resulted in progressive tumor growth localized initially to the secondary lymphoid organs then metastasizing to the lung and liver with a typical median survival time of ෂ25-30 days and mortality Ͼ70%.
BMT
Recipient mice were lethally irradiated with 9 Gy in a Mark I
137
Cs irradiator (JL Shephard and Associates, Glendale, CA, USA) 4-6 h before transplantation. Normal C3H/HeN donor bone marrow was obtained from femurs and tibias in RPMI 1640 (GIBCO Laboratories, Grand Island, NY, USA) supplemented with 100 U/ml penicillin and 100 g/ml streptomycin (GIBCO Laboratories). T cell-depleted bone marrow (ATBM) was prepared by incubating the cells in cytotoxicity medium (RPMI 1640 containing penicillin, streptomycin and 0.3% BSA) containing anti-Thy 1.2 (HO-13.4) on ice for 60 min. The cells were washed and treated with Low Tox M rabbit complement (Cedarlane Laboratories, Westbury, NY, USA) in cytotoxicity medium at 37°C for 60 min. This treatment typically reduced the percentage of Thy1 ϩ cells to Ͻ1%. On day 0, irradiated C3H/HeN recipient mice were reconstituted with 5 ϫ 10 6 ATBM cells i.v. via the tail vein. Beginning on the day of BMT, mice were injected i.p. for 21 days with either CsA at a dosage of 15 mg/kg/day or the control diluent olive oil (Sigma Chemical, St Louis, MO, USA). The animals were weighed three times weekly and observed for clinical symptoms of SGVHD (weight loss, diarrhea). Weight loss over three consecutive weighings and/or the development of diarrhea was considered positive for induction of SGVHD.
SGVHD-mediated tumor rejection and second tumor challenge
To analyze the antitumor potential of SGVHD mice, groups of control (OO-ATBM) and CsA-treated (CsA-ATBM) mice were challenged 7 days after cessation of CsA treatment i.v. with varying numbers of the syngeneic 38C13 B cell lymphoma, 38C13 (OO-38C13, CsA-38C13). Following tumor injection the animals were monitored for SGVHD induction and mortality. Moribund animals were killed by CO 2 asphyxiation and counted as mortalities. In addition, survivors of the first tumor injection were challenged at various times after first injection with 500 38C13 cells. The animals were then monitored as described above. To immunize normal animals with the 38C13 tumor, C3H/HeN mice were given monthly i.p. injections of 1 ϫ 10 7 5000R irradiated 38C13 cells for 2 months. Two weeks after the last injection, the animals were challenged with 500 cells i.v. and monitored for mortality.
Histological analysis
Two to 4 weeks after tumor injection groups of OO-ATBM, OO-38C13, CsA-ATBM and CsA-38C13 animals were killed, tissue samples were removed and placed into 10% buffered formaldehyde. Fixed tissues were embedded in paraffin, cut into 4-sections and stained with hematoxylin and eosin. The induction of SGVHD was monitored by the analysis of liver and large intestine pathology. Histological grading of SGVHD and tumor growth was analyzed without knowledge of treatment groups as follows. 
SGVHD grading
RT-PCR
Single cell spleen cell suspensions were prepared from C3H/HeN mice and splenic B cells were enriched by negative selection using anti-CD4 (GK1.5) and anti-CD8 (53-6.72) treatment, followed by magnetic bead separation (PerSeptive Diagnostics, Cambridge, MA, USA). Following magnetic bead separation, the cells were allowed to adhere to plastic for 2 h to remove adherent cells. 5 ϫ 10 6 nonadherent cells (enriched splenic B cells) or 38C13 cells were placed into 25 cm 2 flasks in RPMI medium containing 10% FCS, 2 mm l-glutamine, 100 U/ml penicillin, 100 g/ml streptomycin, 0.5 mm sodium pyruvate and 5 ϫ 10 Ϫ5 m 2-mercaptoethanol. The cells were cultured in the presence or absence of 100 U/ml recombinant mouse IL-4. Twenty-four hours after initiation of culture, the cells were harvested and total RNA was prepared by Trizol extraction (GIBCO Laboratories). One microgram mRNA was reverse-transcribed to cDNA using oligo-dT priming and AMV reverse transcriptase (Promega, Madison, WI, USA). For RT-PCR analysis of CIITA mRNA, cDNA was amplified in 50 l reaction volumes in a standard PCR reaction. Primer sequences for mouse ␤-actin: sense, 5Ј-GTG GGC CGC TCT AGG CAC CA-3Ј; anti-sense, 5Ј-CGG TTG GCC TTA GGG TTC AGG GGG G-3Ј; for human CIITA, 30 sense, 5Ј-CAA GTC CCT GAA GGA TGT GGA-3Ј; anti-sense, 5Ј-ACG TCC ATC ACC CGG AGG GAC-3Ј. These primers detect cDNA fragments of 245 bp for ␤-actin and 491 bp for CIITA. Annealing was performed at 58°C. After the PCR amplification reaction, the products were analyzed by ethidium bromide staining in agarose gels.
Cytotoxicity assays
Two and 4 weeks after tumor challenge, groups of three OO-ATBM, OO-38C13, CsA-ATBM and CsA-38C13 mice were killed and the spleens were removed. As a positive control for the NK assay, an additional group of C3H/HeN mice was injected i.p. with 100 g of poly I:C (Sigma, St Louis, MO, USA) 18 h prior to assay. Single cell spleen cell suspensions were prepared and tested for the ability to lyse 51 Cr-labeled YAC-1, P815 or 38C13 cells in a standard 4 h chromium release assay. All assays were run at E:T ratios of 100:1 and 30:1. Percent cytotoxicity was calculated as: 100 ϫ (experimental c.p.m. Ϫ spontaneous c.p.m.)/(total release c.p.m. Ϫ spontaneous c.p.m.).
Statistical analysis
Survival analysis was performed using the log rank test. The analysis of GVHD grade and tumor growth was performed by Student's t-test.
Results
While previous work from this laboratory and others has demonstrated induction of SGVHD following CsA treatment of lethally irradiated mice, 17, 27, 28, 31 the GVL potential of SGVHD has yet to be analyzed in murine models. Therefore, the current studies were initiated to examine the ability of murine CsA-induced SGVHD to mediate an antitumor or GVL response against a transplantable syngeneic tumor.
SGVHD-mediated antitumor responses
To determine if antitumor immune mechanisms were active in C3H/HeN SGVHD mice, the capacity to reject a challenge of the C3H class II Ϫ B cell lymphoma 38C13, was monitored by mortality. As shown in Figure 1 and Table 1 , Mice were induced for SGVHD and challenged with 38C13 cells 1 week after CsA as described in Figure 1 .
a Clinical symptoms were measured as weight loss over three consecutive weighings and/or development of diarrhea. CsA-38C13 mice were compared to control OO-38C13 mice of a given tumor cell inoculum using the log rank test. MST = median survival time in days after tumor challenge.
the induction of SGVHD resulted in 30% mortality (CsA-ATBM) (experiment 1). Following injection of 500 38C13 cells, control OO-ATBM tumor-bearing mice (OO-38C13) began to die within approximately 3 weeks and had an MST of 34 days (Table 1) . In contrast, a significant increase in survival (73% vs 25%; P = 0.0178), as well as MST (Ͼ80 days vs 34 days) was observed when CsA-ATBM mice were challenged with 38C13 (CsA-38C13) compared to control tumor-bearing mice. SGVHD mice were unable to reject a challenge with graded numbers 1000 to 5000 38C13 cells (data not shown). However, when challenged with 500 38C13 cells, either enhanced survival and/or increased MST was observed in all experiments. In a similar experiment, Table 1 , experiment 2, the GVL effect mediated by SGVHD did not appear to correlate with clinical symptoms of the disease in that a significant increase in survival and MST was obtained in the absence of clinical symptoms of SGVHD. Less than 13% of the CsA-ATBM animals developed clinical symptoms and Ͼ96% of the CsA-38C13 mice survived, compared to 30% in the OO-38C13 group (P = 0.0001). These findings, however, are consistent with our previous observation that a high percentage of CsA-ATBM mice which did not exhibit clinical symptoms had histologic evidence of SGVHD (ie colonic and hepatic inflammation). 28 
Histological analysis of SGVHD and tumor growth
The above experiments demonstrated that the development of SGVHD resulted in the production of an antitumor response. As an endpoint to determine the effects of SGVHD on tumor growth, the histologic level of tumor burden in various organs was correlated with the induction of SGVHD. Spleen, superficial inguinal lymph node, liver, large intestine and lung tissue samples were obtained from OO-ATBM, CsA-ATBM and OO-38C13 and CsA-38C13 mice injected with PBS or 500 38C13 cells 2 weeks earlier and analyzed histologically. Initial studies concentrated on the analysis of inflammation of the target organs of murine SGVHD: liver and large intestine. 17, 27, 28 As expected, sections of liver from OO-ATBM (Figure 2A ) or OO-38C13 animals ( Figure 2B ) showed no evidence of inflammation in or around the portal area. Conversely, the portal areas of livers isolated from CsA-ATBM ( Figure 2C ) or CsA-38C13 ( Figure 2D ) mice showed significant infiltrate when compared to the control animals. The large intestine from CsA-treated recipients but not control animals demonstrated inflammatory lesions of the mucosal layer including crypt abscess formation and mucosal ulceration as published previously (data not shown).
17
When the tissues from the OO-38C13 mice were examined for the presence of lymphoma cells, expansion of tumor was found in the liver ( Figure 2B ), spleen, lymph nodes and lung (data not shown). However, when the same organs isolated from most CsA-38C13 mice were examined, a reduction or complete elimination of 38C13 cells was observed. The reduction of tumor burden in the liver ( Figure 2D ) spleen and lung of CsA-treated SGVHD was further evidence of the SGVHD-derived antitumor response. When the tissues from control and SGVHD mice were graded histologically after challenge for tumor growth, significant reduction in growth was observed in the liver and lung of CsA-treated mice over that observed in organs isolated from control tumor-bearing animals ( Figure  3) . Furthermore, when tumor growth in all organs was compared to CsA treatment vs control therapy, significant reduction in tumor growth was observed. In most instances, altered tumor growth correlated with the presence of histologically identifiable inflammatory responses in the target organs of SGVHD. Comparison of the GVHD grade in the liver, a target organ of SGVHD, with tumor growth in the various tissues, revealed that increased GVHD-associated pathology was correlated with a significant reduction in tumor growth in the spleen (P = 0.0029), liver (P = 0.0024), lung (P = 0.00004) and when all organs were grouped together (P = 0.0047). Similar results were obtained when the level of GVHD in the colon was compared to tumor growth (data not shown). Finally, it should be noted that not all of the CsA-treated mice rejected challenge with 38C13 cells. Tumor progression occurred in some CsA- 38C13 mice, but was associated with minimal evidence of SGVHD induction.
Secondary challenge of long-term survivors
The previous results demonstrated that mice which had been induced for the development of SGVHD, could reject a first tumor challenge with 38C13 cells. It was therefore important to determine if these animals had developed long-term memory antitumor immunity. Eighty-five days after first tumor injection, long-term OO-ATBM, CsA-ATBM, OO-38C13 and CsA-38C13 survivors were given a second autologous tumor challenge with 500 38C13 cells ( Table 2) . Regardless of the treatment group prior to the first tumor injection, all animals succumbed to the second challenge and no consistent differences in MST or overall survival were observed between the various treatment groups. To determine if the 38C13 B cell lymphoma was immunogenic and could elicit a memory immune response in normal syngeneic mice, C3H/HeN mice were immunized with 1 ϫ 10 7 irradiated 38C13 cells, then challenged with 500 autologous tumor cells (Figure 4 ). There was a slight but not significant increase in the MST and no significant difference in survival between immunized or nonimmunized C3H/HeN mice challenged with 500 38C13 cells. These results demonstrated that the class II Ϫ tumor is relatively nonimmunogenic and did not induce a memory antitumor response in normal immunized animals or CsA-38C13 SGVHD animals that had rejected a primary tumor challenge.
Induction of MHC molecules on 38C13 cells
Self-class II-reactive, CD8
ϩ CTL have been proposed to be the putative effector cell of CsA-induced rat SGVHD 25 and human autologous GVHD, 18 as well as potential GVL responses associated with these diseases. 18, 24 However, preliminary experiments suggested that the 38C13 B cell lymphoma utilized in this report did not express class II antigens. IL-4 and IL-10 have been shown to induce MHC class II antigen expression on B cells, [32] [33] [34] while IFN-␥ induces the expression of class I and II on a variety of cell types. 35 With this in mind, experiments were performed to determine if MHC class II antigen expression on 38C13 These results suggested that a defect existed in the ability to transcribe or translate the class II genome in the 38C13 tumor line. The class II transactivator (CIITA) 36 has been shown to act as a master-regulator of MHC-class II expression. 37, 38 Experiments were performed to determine if the defect in class II expression by 38C13 cells was related to CIITA expression. Normal B cells and 38C13 cells were cultured in media alone or in the presence of IL-4 for 24 h. At the end of the culture period, RNA was extracted from the cells and analyzed by RT-PCR for the presence of CIITA mRNA. PCR primers from the human CIITA sequence were utilized 30 and have been shown to amplify both human and mouse CIITA mRNA. 30, 39 As shown in Figure 6 , CIITA mRNA increased in B cells stimulated with IL-4, relative to untreated control cells (lane 2 vs 3). Conversely, no class II transactivator CIITA mRNA was detected in either untreated or IL-4-treated 38C13 cells (lanes 4 and 5). These data in total demonstrate that the 38C13 B cell lymphoma cells do not express MHC class II genes and are deficient for the transactivator required for their transcription. Therefore, class II cannot be considered a target for tumor rejection in this system.
Enhancement of NK activity in spleens of tumor challenged SGVHD mice
The effector mechanisms responsible for murine SGVHDmediated GVL remain unknown. In vitro experiments were performed to analyze whether tumor-specific CTL or NK cells were present in the spleens of tumor-challenged or control mice. Spleen cells from OO-ATBM, CsA-ATBM or OO-38C13 and CsA-38C13 mice challenged 2 or 4 weeks earlier with 500 38C13 cells were tested in a 4 h chromium release assay for the ability to lyse chromiumlabeled NK-sensitive YAC-1 cells, NK-resistant P815 cells, or 38C13 cells. Experiments analyzing the ability of CsA-38C13 survivors to reject a second tumor challenge suggested that memory antitumor immunity (T cell) did not develop in these animals. Consistent with this finding, spleen cells isolated from CsA-38C13 mice both at 2 (Table  3 ) and 4 weeks (data not shown) failed to react against the autologous 38C13 tumor cells. However, enhanced NK activity by CsA-38C13 spleen cells was observed against YAC-1 cells. This reactivity was higher at 2 weeks (Table  3 ) and began to wane at 4 weeks (data not shown). No reactivity was observed against the NK-resistant P815 cell line, and the reactivity against YAC-1 cells was removed by treatment with anti-asialo GM1 antisera (data not shown), confirming that cytotoxity was mediated by NK cells. As a positive control for the NK assay, normal C3H/HeN mice were injected with pI:C 18 h before the assay to enhance NK activity. These activated NK cells could lyse the 38C13 tumor cells, indicating that the tumor cells were sensitive to lysis by activated NK cells. Table 3 Spleen cells from tumor-challenged SGVHD mice exhibit enhanced NK but not CTL activity 
Discussion
It has been shown that relapse rates for cancer patients who receive allogeneic BMT and develop GVHD are lower than those for patients who do not. 8 This phenomenon has been termed the graft-versus-leukemia or graft-versus-tumor (GVT) effect. Cyclosporin A-induced syngeneic and autologous GVHD has been observed experimentally in rodents [15] [16] [17] and clinically in cancer patients. [18] [19] [20] [21] [22] [23] The data presented in this report demonstrate that a GVT mechanism is present in mice with SGVHD. Mice in which SGVHD was induced rejected a minimal tumor challenge of a class II Ϫ B cell lymphoma after cessation of CsA therapy and the rejection coincided with histological evidence of the disease. Long-term survivors of the initial tumor injection did not reject a second tumor challenge, suggesting that long-term immunity did not develop in these animals. The increased survival and MST in the absence of long-term antitumor immunity is consistent with enhanced natural immunity, ie NK cells, macrophages, in the rejection of the class II Ϫ 38C13 B cell lymphoma. CsA-induced SGVHD in rats and clinical autologous GVHD in humans is thought to be mediated by class IIrestricted autoreactive CD8 ϩ CTL. 18, 24, 25 Such cells have been shown to be active in vitro against class II ϩ tumor cells. It has therefore been proposed that these unique CD8 ϩ CTL may have the potential to mediate a GVT response. 24, 25 With this in mind, Noga et al recently examined the GVT capacity of rats with SGVHD and antitumor immunity was observed against class II ϩ tumors. Furthermore, in vivo treatment with IFN-␥ potentiated the GVT effect. 25 These results suggested that a requirement existed for tumor MHC class II expression. In contrast, the role of tumor class II expression appeared to differ in the mouse model of SGVHD-GVT in that mice were resistant to the 38C13 B cell lymphoma which did not constitutively express class II Ag and was not inducible for class II by treatment with cytokines known to induce the expression of class II genes on B cells. [32] [33] [34] Furthermore, additional studies revealed that the 38C13 tumor cells did not express mRNA for the class II transactivator, CIITA. CIITA expression has been shown to be important for MHC class II expression [36] [37] [38] [39] and transfection of mouse cells with the human CIITA gene resulted in the upregulation and detection of class II in the transfected cells. 30 The failure to detect MHC class II antigens either on the surface of 38C13 cells or intracellularly, as well as, the inability to demonstrate mRNA for CIITA, suggested that tumor class II expression did not occur, and thus was not required for the GVT responses against the 38C13 B cell lymphoma. However, tumor class II expression could mediate activation of immune mechansims that result in the rejection of larger numbers of tumor cells or the development of tumor-specific memory immunity. Studies to analyze the role of tumor class II expression in the development of SGVHD-GVT-mediated tumor-specific immunity are currently in progress using a class II ϩ C3H myeloid tumor. The use of the C3H/HeN murine model offers an excellent opportunity to study the antitumor effects of this disease. Since the disease is inducible in a high percentage of the animals, 27, 28 and is generally self-limiting, the use of this strain appears to mimic the desired clinical outcome of CsA-induced GVHD: high percent induction with low morbidity and mortality. The data presented in this paper is the first report in which mice which are inducible for SGVHD have been shown to develop mechanisms which mediate the rejection of a tumor challenge following cessation of CsA treatment. It was demonstrated upon microscopic examination, that the development of histologically identifiable inflammatory lesions in SGVHD target organs (liver and large intestine) was associated with a reduction in tumor growth in the spleen, liver and lungs. It is likely that the tumor first encounters the immune system as it localizes to the spleen, liver and lungs within 2 h after challenge (data not shown) and that elimination of tumor may occur at these sites.
Other investigators have attempted to utilize CsA therapy after syngeneic BMT to induce antitumor responses. Charak et al 40 have analyzed the effect of IL-2 and CsA treatment following syngeneic BMT. The animals mediated an antitumor response but it differed from the model presented in this manuscript in that IL-2 was required for tumor therapy. Unlike the system utilized in this report, CsA treatment alone was insufficient to result in tumor rejection. Similar experiments were designed by Hashino et al 41 in which irradiated mice were reconstituted with syngeneic BM and treated with CsA or FK506 for 2 weeks or 30 days, respectively. While these animals had an apparent increase in NK activity in vitro, the animals did not have clinical or histological evidence of SGVHD, nor did they reject a challenge with syngeneic tumor. Finally, in a recent study by Singhal et al, 42 Balb/c mice (a noninducible strain for SGVHD when reconstituted with whole BM) 27 were irradiated, reconstituted with BM and treated with CsA for 30 days and analyzed for the development of SGVHD and the ability to reject syngeneic tumor challenge. SGVHD did not develop and no antitumor effect was observed in these animals. Bryson et al 17, 27 have demonstrated that the induction of SGVHD is strain and age-specific. Furthermore, the removal of Thy 1 ϩ BM cells prior to BMT was required for SGVHD to develop upon cessation of CsA in some strains of mice. 28, 29 It is likely that the induction protocols utilized by others [40] [41] [42] did not meet the appropriate conditions required to induce murine SGVHD and thus the ability of SGVHD to mediate tumor therapy may not have been measured by these studies.
The effector mechanisms responsible for tumor rejection in the present study appeared to be non-specific. Long-term survivors did not exhibit immunologic memory when given a second challenge with homologous 38C13 tumor cells. Since the 38C13 tumor is relatively non-immunogenic to syngeneic C3H/HeN mice and only a minimal tumor challenge is rejected in this system, a specific antitumor immune response may not have been generated and/or was below the threshold of the in vitro cytotoxicity assay. In addition to CTL responses, CD4
ϩ T cells could participate in SGVHD-mediated antitumor responses. We have in fact isolated CD4
ϩ , class II-reactive T cell clones from animals late in the SGVHD disease process. 43 These autoreactive T cell clones mediated footpad swelling when injected into irradiated syngeneic recipients. However, these cells were of the T H 2 T helper phenotype, producing IL-4 and IL-10 (unpublished data). It could be speculated that such cells may have served a regulatory role in the C3H/HeN SGVHD mouse, resulting in a down-modulation of the disease process in these animals resulting in the self-limiting nature of SGVHD in C3H/HeN mice. Based on the T helper profile of these clones it is unlikely that such cells would participate in an antitumor response.
While CTL responses could not be demonstrated, enhanced NK activity was observed using spleen cells isolated from the SGVHD tumor-bearing mice when compared to the control tumor-challenged animals. NK cells have been shown to participate in innate resistance that is nonspecific, does not require prior sensitization and have been shown to kill tumor cells spontaneously. Data from Kosugi and Shearer, 44 as well as unpublished data from our laboratory have demonstrated that NK activity is increased in the first 1-2 weeks after cessation of CsA therapy. While we were able to demonstrate that enhanced NK activity was present in SGVHD-tumor-bearing mice 2-4 weeks after tumor injection, it did not translate into lysis of the 38C13 cells in vitro. The tumor appeared to be resistant to NK lysis. A more important feature of the enhanced NK activity may lie in the production of IFN-␥ and TNF-␣. At the time of tumor challenge, preliminary experiments have shown that IFN-␥, TNF-␣ and IL-12 production is elevated in target tissues isolated from SGVHD mice (unpublished data). IFN-␥ is a potent activator of macrophages and activated macrophages have been shown to kill tumor cells which are resistant to T cell and NK cell mediated lysis. 45, 46 Finally, IL-12 is produced by activated macrophages 47 and has been demonstrated to enhance NK cytotoxicity, 48 induce IFN-␥ and TNF-␣ [48] [49] [50] [51] production by NK cells and mediate tumor rejection. 52 It is interesting to speculate that IL-12 may be an important effector molecule in this system. These studies have demonstrated that animals with cyclosporin A-induced SGVHD possess the ability to mediate a GVT response against an MHC class II Ϫ tumor. Future experiments will compare SGVHD-mediated tumor rejec-tion of MHC class II ϩ and class II Ϫ tumor to determine the cell-mediated immunity which develops against these tumors. The ability to unravel the multifaceted immune response in this system may allow for further manipulation directed to optimize the antitumor responses observed in these animals.
